Solorank
Login

Cached score snapshot

US.BIIB · Biogen

110分制 66/110；5D動能v2 17/50；排序分 83/160

Back to ranking Open volume snapshot
Ranking score 83/160
Main score 66/110
5D momentum v2 17/50
Rank #40
Setup grade B 69.2

Score breakdown

謹慎買入

Medium twelvedata

Score and price trend

B 69.2 lift 1.27x

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 08-05 09-08 10-09 11-11 12-09 $195.64$234.47$273.30 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling calibration best · score 2.541 · anchors 120 +1.44% +0.24% / +3.29% 82.5% 0% Actual outcome pending · 1 / 3 bars observed
30D observation -1.97% -7.90% / +4.85% 40% 37.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.75% -1.01% / +2.89% 61.9% 3.1% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-08-05 → 2026-12-09 · 90 archived points · 3 Improving turn signal · 10 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 83
Display grade 謹慎買入
Model version cursor_18_27_news_v2_160
Main score 66/110 (謹慎買入)
5D momentum v2 17/50 (弱)
Score with momentum v2 83/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 234.287
ma50 225.731
close 244.05
prevClose 252.73
avgVolume20 1338321
volumeRatio 1.74
changePercent -3.43

Metrics snapshot

close 244.05
volume 2324716
changePercent -3.43

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 66/110
Main rating 謹慎買入
5D momentum v2 17/50
Score with momentum v2 83/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.3/5 · 較差
Dimension score 2.3/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.3
epsPoints 0
roePoints 0
debtPoints 0.5
marginPoints 0
turnoverUsdM 567.3469
volumePoints 0.5
revenuePoints 0
dividendPoints 0
marketCapPoints 0.5

資金流 — 13.2/20 · 一般
Dimension score 13.2/20
Dimension grade 一般

Sub-items

cmfPoints 0.8
mfiPoints 3.2
obvPoints 3.2
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.BIIB
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 11.8/15 · 良好
Dimension score 11.8/15
Dimension grade 良好

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 17.52

trend

score 3.4

details

qqq

ma20 732.4765
ma50 725.4244
name QQQ
close 725.61
points 1.4

spy

ma20 770.8955
ma50 767.626
name SPY
close 772.31
points 2
source twelvedata+fred
atrPct 3.264
atrPoints 2
cciPoints 4
vixPoints 2.4
marketTrendPoints 3.4

催化劑 — 6/20 · 較差
Dimension score 6/20
Dimension grade 較差

Sub-items

catalyst

score 6

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 1
catalystPoints 6

風險管理 — 6.5/10 · 一般
Dimension score 6.5/10
Dimension grade 一般

Sub-items

position

score 1.3

details

atrPct 3.264
turnoverUsdM 567.3469
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.BIIB
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 228.1186

strength_details

ma_score 1.5
atr_score 1
rsi_score 0.5
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 6.5
take_profit_price 261.2028
target_multiplier 1.9
technical_strength 1.7
take_profit_percent 7
positionPoints 1.3
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 6.5279
diversificationPoints 2

技術信號 — 20.2/30 · 一般
Dimension score 20.2/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 0.9
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 0.9
vcp_reason 站上MA50；升放量(近10日4日)；Ready=N；Confirm=N

vcp_metrics

up_days 6
vol_ref 1269783.3333
down_days 3
vcp_ready false
above_ma50 true
avg_vol_10 1398420
avg_vol_20 1299750
avg_vol_30 1269783.3333
range_pct_10 0.1082
range_pct_20 0.1585
range_pct_30 0.1632
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok false
up_expand_days 4
breakout_20d_ok false
vol_ratio_10_30 1.1013
dist_to_20d_high 0.0407
down_shrink_days 2
breakout_level_20d 254.41
vcp_breakout_confirm false
contraction_ratio_10_30 0.6632
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 6/10 · 一般
Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 4
sentimentScoreRaw 1.2

sentimentData

raw {"id":143261009,"url":"https://finnhub.io/api/news?id=3f10b0470f74ce88e789b68777ecd0afd9b8e3b684a5b3f44301080da48a2754","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Growth portfolio revenue jumped 49%, now 63% of core pharma sales.","category":"company","datetime":1793207624,"headline":"Biogen (BIIB) Q3 2026 Earnings Call Transcript"}, {"id":143261010,"url":"https://finnhub.io/api/news?id=e40ac030393c1087fc34195b0c8660b2063a0cd4ccf2116169c4ab1c56573ca6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.","category":"company","datetime":1793203860,"headline":"BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened"}, {"id":143262321,"url":"https://finnhub.io/api/news?id=c072351f36fb2ad19734be7692214840661ef52fadc9a3fbde57aefc2d310b7a","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"BIIB","summary":"Biogen Inc. (BIIB) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...","category":"company","datetime":1793203257,"headline":"Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript"}, {"id":143256768,"url":"https://finnhub.io/api/news?id=e66c2cd6a9105bce9ed6d616829743f8e15944612f425b4c3f19a7358be3f369","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1793190604,"headline":"Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates"}, {"id":143256767,"url":"https://finnhub.io/api/news?id=c9f1f0c65d832b0c1eee004a85a679e6e18b4ce44f8f13719a96bf346b5c887e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 2026, with revenue up 10.6% year on year to $2.80 billion. Its non-GAAP profit of $2.62 per share was 32.5% above analysts’ consensus estimates.","category":"company","datetime":1793188492,"headline":"Biogen (NASDAQ:BIIB) delivers impressive Q3 2026"}, {"id":143254954,"url":"https://finnhub.io/api/news?id=a9f487a9153087d8f8f9ec394803ef83663db960aeece8806438536530b918ad","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1793184602,"headline":"Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates"}, {"id":143237260,"url":"https://finnhub.io/api/news?id=120089cfdff5c5eecf5106ab5470c0912020cdfba5a9dcccf6d46644b9621bc6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) heads into a key moment this week, with the biotech group set to report quarterly earnings before the market opens on Wednesday, a focal point for current sentiment. Recent price action has been strong. Biogen’s 1 day share price return of 0.63% and 7 day share price return of 8.04% contribute to a 90 day share price return of 22.69%, with total shareholder return over the past year at 67.69%. This suggests that optimism around upcoming catalysts and recent product updates is...","category":"company","datetime":1793110147,"headline":"Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued"}, {"id":143234677,"url":"https://finnhub.io/api/news?id=67b92752082a6fb569388db66a39d75b3effb46d8721b147d1999fd96c60b4e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen has delivered a strong run over the past year, and the key issue for you now is whether the current share price lines up with the cash the business is expected to generate. After a move like this, the question is how much of Biogen’s future cash flows the market may already be pricing in. Biogen has returned 67.7% over the past year, which puts real pressure on the question of whether recent gains are fully supported by its underlying cash flow potential. Fresh data around EMPAVELI...","category":"company","datetime":1793107171,"headline":"Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data"}
raw_source {"id":143260586,"url":"https://finnhub.io/api/news?id=1d79ccf6f3610d78e9ad26a2d47e9c6c688db90116702300cf2bf2daf22ade2f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Moby summary of Biogen Inc.'s Q3 2026 earnings call","category":"company","datetime":1793208637,"headline":"Biogen Inc. Q3 2026 Earnings Call Summary"}, {"id":143261009,"url":"https://finnhub.io/api/news?id=3f10b0470f74ce88e789b68777ecd0afd9b8e3b684a5b3f44301080da48a2754","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Growth portfolio revenue jumped 49%, now 63% of core pharma sales.","category":"company","datetime":1793207624,"headline":"Biogen (BIIB) Q3 2026 Earnings Call Transcript"}, {"id":143261010,"url":"https://finnhub.io/api/news?id=e40ac030393c1087fc34195b0c8660b2063a0cd4ccf2116169c4ab1c56573ca6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.","category":"company","datetime":1793203860,"headline":"BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened"}, {"id":143262321,"url":"https://finnhub.io/api/news?id=c072351f36fb2ad19734be7692214840661ef52fadc9a3fbde57aefc2d310b7a","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"BIIB","summary":"Biogen Inc. (BIIB) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...","category":"company","datetime":1793203257,"headline":"Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript"}, {"id":143261583,"url":"https://finnhub.io/api/news?id=380d9e75595ab13a3f271bbc2186e20d8075d57c1b72abeef50205567640dcb0","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"BIIB","summary":"2026-10-28. The following slide deck was published by Biogen Inc.","category":"company","datetime":1793199677,"headline":"Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation"}, {"id":143259457,"url":"https://finnhub.io/api/news?id=3a1980846c6a2a79477968f0e6ee7d6538d2b01af709a304ad78345d5af52984","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen Inc. (NASDAQ:BIIB) reported third-quarter 2026 earnings and revenue above analyst expectations on Wednesday, supported by growth across its newer treatments and the first full-quarter contribution from products acquired through its purchase of Apellis in May.","category":"company","datetime":1793195630,"headline":"Biogen Q3 Earnings Beat Estimates as Revenue Rises 11% and 2026 Profit Guidance Improves"}, {"id":143259229,"url":"https://finnhub.io/api/news?id=0a31c4aa1e295543824d9a80799ce3fe05c4bc1fa5a93677f625a2f9369b7390","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"We have a solid slate of reports today, both of the earnings variety and regarding economic growth.","category":"company","datetime":1793194680,"headline":"Big Day for Econ Data, Hyperscaler Earnings"}, {"id":143259051,"url":"https://finnhub.io/api/news?id=f09e9eb855f9f12cb39e161fded1b77da23237f9492fc38b04074ece9e249dd8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.","category":"company","datetime":1793194380,"headline":"How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?"}, {"id":143256768,"url":"https://finnhub.io/api/news?id=e66c2cd6a9105bce9ed6d616829743f8e15944612f425b4c3f19a7358be3f369","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.","category":"company","datetime":1793190604,"headline":"Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates"}, {"id":143256766,"url":"https://finnhub.io/api/news?id=37dbfb4e6b1e3661246a09d898a581825e6492934194bfc57b2d868b43fc5dd5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"If Biogen sat on your watchlist instead of in your portfolio over the past year, the result may feel like a missed shot. Investors who held Biogen over the past year are up 69.5%, including dividends. That outcome sits against a backdrop where analysts in late 2025 were split on whether shrinking revenue, higher margins, and a 3-year P/E reset could work. Which of those business assumptions would you focus on if you were making that call again today? Narratives are how investors here put a...","category":"company","datetime":1793189598,"headline":"What Biogen Doubters Overlooked"}, {"id":143256767,"url":"https://finnhub.io/api/news?id=c9f1f0c65d832b0c1eee004a85a679e6e18b4ce44f8f13719a96bf346b5c887e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 2026, with revenue up 10.6% year on year to $2.80 billion. Its non-GAAP profit of $2.62 per share was 32.5% above analysts’ consensus estimates.","category":"company","datetime":1793188492,"headline":"Biogen (NASDAQ:BIIB) delivers impressive Q3 2026"}, {"id":143254954,"url":"https://finnhub.io/api/news?id=a9f487a9153087d8f8f9ec394803ef83663db960aeece8806438536530b918ad","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1793184602,"headline":"Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates"}, {"id":143254955,"url":"https://finnhub.io/api/news?id=bc71f6f78a47ab607cf5b627b41d4ba7c540ced449d93c9193534eba439aeab3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Investing.com -- Biogen Inc (NASDAQ:BIIB) on Wednesday reported third quarter adjusted earnings per share of $2.62, surpassing the analyst consensus of $2.02 by $0.60. Revenue reached $2.8 billion, exceeding the $2.64 billion estimate and representing an 11% increase from the prior year period.","category":"company","datetime":1793184288,"headline":"Biogen beats Q3 estimates, raises guidance floor on growth"}, {"id":143254958,"url":"https://finnhub.io/api/news?id=1f7c7197ef94647283f364a62f59fdf57b39d74fdce077fb4203a1ec373cf82e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 32.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 203.8 million, which is an increase of approximately 74 percent compared to the royalty recorded by BioArctic for the third quarter of 2025.","category":"company","datetime":1793183220,"headline":"Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026"}, {"id":143254956,"url":"https://finnhub.io/api/news?id=888827508cb920e674aa339923ad30e549d82cbdad45cf9fd064f6dbf91fe2b8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance boost.","category":"company","datetime":1793182287,"headline":"Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report"}, {"id":143254957,"url":"https://finnhub.io/api/news?id=6d39fdd58057f30a155224114223705b28c4566931152024475047c19ad94c70","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.","category":"company","datetime":1793181660,"headline":"Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack."}, {"id":143258376,"url":"https://finnhub.io/api/news?id=a5bae5e39fc2b4daf81ddcb0240db5f6c5ba5c20079563cc74e7dff5d95e1380","image":"https://cdn.benzinga.com/files/images/story/2026/10/28/Stock-market-chart-with-green-candlestic.jpg?width=2048&height=1536","source":"Benzinga","related":"BIIB","summary":"Biogen (NASDAQ:BIIB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For","category":"company","datetime":1793180793,"headline":"Biogen Q3 2026 Earnings Call Transcript"}, {"id":143258377,"url":"https://finnhub.io/api/news?id=b511fe2d632727e3e2f35a35ff3ae506da4f1c83ecd499126e645912886e9662","image":"","source":"Benzinga","related":"BIIB","summary":"- Conference Call","category":"company","datetime":1793177147,"headline":"Biogen Exec Expects Growth From Apellis Acquisition Even Without The Pipeline"}, {"id":143258378,"url":"https://finnhub.io/api/news?id=ab28e1c0a340a8e906c10614d797de84d929fc8062f2b0acc9ad1726439de942","image":"","source":"Benzinga","related":"BIIB","summary":"https://event.webcasts.com/viewer/event.jsp?ei=1771787&tp_key=52bcd10df0","category":"company","datetime":1793176933,"headline":"Biogen Exec Says Expecting Growth From Apellis Acquisition Even Without The Pipeline; Our Ambition Is Over The Next Few Years To Have At Least 20 Programs In Early Stage Development"}, {"id":143258379,"url":"https://finnhub.io/api/news?id=a3c51f910ea089c6594ee53ae8779640cf42d322ff46fda27d60b35946fe468e","image":"","source":"Benzinga","related":"BIIB","summary":"Biogen (NASDAQ:BIIB) narrows FY2026 Adj EPS guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 analyst estimate..","category":"company","datetime":1793167612,"headline":"CORRECTION: Biogen Narrows FY2026 Adj EPS Guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 Est"}, {"id":143258380,"url":"https://finnhub.io/api/news?id=9e8e519ee3ff9f88eed98e5e0b662e3c734d10ffa6be358d7e755788addc94d1","image":"","source":"Benzinga","related":"BIIB","summary":"Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $12.20-$13.00 vs $12.36 analyst estimate..","category":"company","datetime":1793167327,"headline":"Biogen Raises FY2026 GAAP EPS Guidance from $12.00-$13.00 to $12.20-$13.00 vs $5.84 Est"}, {"id":143237260,"url":"https://finnhub.io/api/news?id=120089cfdff5c5eecf5106ab5470c0912020cdfba5a9dcccf6d46644b9621bc6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) heads into a key moment this week, with the biotech group set to report quarterly earnings before the market opens on Wednesday, a focal point for current sentiment. Recent price action has been strong. Biogen’s 1 day share price return of 0.63% and 7 day share price return of 8.04% contribute to a 90 day share price return of 22.69%, with total shareholder return over the past year at 67.69%. This suggests that optimism around upcoming catalysts and recent product updates is...","category":"company","datetime":1793110147,"headline":"Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued"}, {"id":143234677,"url":"https://finnhub.io/api/news?id=67b92752082a6fb569388db66a39d75b3effb46d8721b147d1999fd96c60b4e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen has delivered a strong run over the past year, and the key issue for you now is whether the current share price lines up with the cash the business is expected to generate. After a move like this, the question is how much of Biogen’s future cash flows the market may already be pricing in. Biogen has returned 67.7% over the past year, which puts real pressure on the question of whether recent gains are fully supported by its underlying cash flow potential. Fresh data around EMPAVELI...","category":"company","datetime":1793107171,"headline":"Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data"}, {"id":143233087,"url":"https://finnhub.io/api/news?id=74aab667e93c48b17302c90a31f34ca9928c6d3a47a5857ea90b05480fafc1a3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Wednesday before market open. Here’s what to look for.","category":"company","datetime":1793096567,"headline":"Biogen earnings: what to look for from BIIB"}, {"id":143204994,"url":"https://finnhub.io/api/news?id=66f63e0574940212ee3b29263edc38410fe307dec9128ccd68e63f19c8dbce9e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Kos Biotechnology Partners (\"Kos\"), a global life sciences investment firm bridging the U.S. and European biopharma ecosystems, today announced a strategic investment in Golden Age Health (GAH) through its inaugural fund, Kos BioVentures. As part of this partnership, Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners, will join the Golden Age Health Board of Directors.","category":"company","datetime":1793052180,"headline":"Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies"}, {"id":143202832,"url":"https://finnhub.io/api/news?id=7b8c988faaf29be1070f93a78eba578a30276fb5ea8f0464c621319420abd6f2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.","category":"company","datetime":1793042220,"headline":"Corxel, an obesity drugmaker, to go public via SPAC deal"}, {"id":143197963,"url":"https://finnhub.io/api/news?id=16a7bc6d08aceeea8f390458bad4f92e66e9dfc2d8069874e0beca1b6575ad2b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.","category":"company","datetime":1793018280,"headline":"Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?"}, {"id":143191497,"url":"https://finnhub.io/api/news?id=f113f7c826dfccdc8930bdf4db309c7b85cb6fbb111034d7b4c7ec7809e2cc0a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"For questions about this article or underlying research, email help@trefis.com.","category":"company","datetime":1792998707,"headline":"Can Corcept Therapeutics Stock Rally 40% After This Dip?"}, {"id":143191625,"url":"https://finnhub.io/api/news?id=f488331be4fc0aabb6b91d631958c54c2e6eedde32af3d9e4b889a6a1c65305b","image":"","source":"SeekingAlpha","related":"BIIB","summary":"","category":"company","datetime":1792987500,"headline":"Baron Health Care Fund: Q3 2026 New Positions And Exits"}, {"id":143132469,"url":"https://finnhub.io/api/news?id=8d7c4734f1737893dbcd9e02eb809a58ba77d9c2c5f439008bb8400a9de59eb1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.","category":"company","datetime":1792750740,"headline":"Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?"}, {"id":143104128,"url":"https://finnhub.io/api/news?id=2b8d6979c1a213c87a4ba1f8a01170b9797ae35df10f79cd3d6a38a120ede13f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Key TakeawaysBiogen shares rose 5% today after BofA raised its price target to $244 from $219 and kept a Neutral rating. BofA’s new target is close to the $247 consensus target, which has climbed 43% over the past year as analysts try to keep up with the stock.","category":"company","datetime":1792702326,"headline":"Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3"}, {"id":143102773,"url":"https://finnhub.io/api/news?id=0a2a907a5898714f245153f9c44f38d24520e82c941a5134ed19de6477214e44","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1792674009,"headline":"Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"}, {"id":143101191,"url":"https://finnhub.io/api/news?id=77cc35f119852aa14aa59bb6baea57ab8b24608570e9b377887056e484594750","image":"","source":"Benzinga","related":"BIIB","summary":"B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.","category":"company","datetime":1792654702,"headline":"B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244"}, {"id":143070296,"url":"https://finnhub.io/api/news?id=ddc6e1144b1bd498cc2fca211d0682d66fc2d11daddebb95133578b52647a3d2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1792587618,"headline":"Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release"}, {"id":143067862,"url":"https://finnhub.io/api/news?id=84a790847668ebb238e90facc3949ebb837ce3c4520939792a11d2dcc6cf93b9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.","category":"company","datetime":1792584360,"headline":"The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics"}, {"id":143069839,"url":"https://finnhub.io/api/news?id=46c5a51c20d04bf20555bdeae73e41626773be092b9cb0aaba68f1c80fc4748b","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254102883/image_2254102883.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BIIB","summary":"Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock here.","category":"company","datetime":1792582262,"headline":"Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm"}, {"id":143069179,"url":"https://finnhub.io/api/news?id=4268518ed28f3e77559414e68b7f1071953c46e77bf731c62334a41314eee89f","image":"","source":"Benzinga","related":"BIIB","summary":"TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.","category":"company","datetime":1792576437,"headline":"TD Cowen Maintains Buy on Biogen, Raises Price Target to $250"}, {"id":143031147,"url":"https://finnhub.io/api/news?id=644dd6ec18767427693e2fe0f20c8e8cc753f3fb6de07218e5f1d48be6f44f23","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head of Equity Strategy Lori Calvasina noted that Healthcare historically moves inversely to Technology’s relative performance versus the S&P 500, making it a natural destination when r","category":"company","datetime":1792524424,"headline":"RBC Capital names top healthcare stocks as sector upgraded to overweight"}, {"id":143031680,"url":"https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"BIIB","summary":"S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.","category":"company","datetime":1792514161,"headline":"S&P 500 Top Movers: Gainers and Losers From Today's US Session"}, {"id":143029159,"url":"https://finnhub.io/api/news?id=f479ad2df5936d859f53f8c84a798333a56d9d576d6101676e3408d578046dc5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.","category":"company","datetime":1792503000,"headline":"4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now"}, {"id":143025571,"url":"https://finnhub.io/api/news?id=3bad8a224e7ed91550e1b91d6b1e29ab595863dc9bd082ea62f67e3e3620a61a","image":"","source":"Benzinga","related":"BIIB","summary":"Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.","category":"company","datetime":1792490147,"headline":"Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310"}, {"id":143006658,"url":"https://finnhub.io/api/news?id=128f392596d085f3a087a2d4ba623a478b80c0f19e3bbeaab0568482cbae6a3e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.","category":"company","datetime":1792411200,"headline":"AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results"}, {"id":143005875,"url":"https://finnhub.io/api/news?id=4ee66815d7416467592281892f43dbf5a66333fe7e9a275b9718728c2bd720d7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured CAMBRIDGE","category":"company","datetime":1792409400,"headline":"Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week"}, {"id":143006438,"url":"https://finnhub.io/api/news?id=d54e48dd82215b7c03c46d22f4fb67787dc5f58177306ba2eae9c9a7c5e50530","image":"","source":"Benzinga","related":"BIIB","summary":"Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of","category":"company","datetime":1792395141,"headline":"Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week"}, {"id":142954484,"url":"https://finnhub.io/api/news?id=566b777de47cf4258a817a60d513bcb7ddc7645f2b14d60abe037a9814ff7172","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"JPMorgan strongly reset its price target on the company’s attractive 2027 pipeline catalysts.","category":"company","datetime":1792197420,"headline":"A kidney transplant milestone has Wall Street excited about Biogen"}, {"id":142950200,"url":"https://finnhub.io/api/news?id=b1fa0d753cf23ca6d1367c84b71f611b5973b1c128e237773dd2d8fd0e33782a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"It's another risk-off day for the broader market, with tech taking another tumble, thanks to a continued slide for semiconductor stocks.","category":"company","datetime":1792172809,"headline":"Another Biotech IPO Pops on Rough Day for Broader Market"}, {"id":142944427,"url":"https://finnhub.io/api/news?id=9d0c8c9629cbfe7d9c78c8a89266ac9138c21201484802bea94c0a2c6af6bdc4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as \"ADPKD.\"","category":"company","datetime":1792146600,"headline":"Biogen-backed Estuary nabs $93M for kidney disease gene therapy"}, {"id":142944885,"url":"https://finnhub.io/api/news?id=f91f403f3ffc3a12e9d0386f0f23990216287021ab63ad0404ebea0e9b7ed963","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BIIB","summary":"Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimer’s revenue growth, and key risk/reward drivers—read now. Click for this BIIB update.","category":"company","datetime":1792139325,"headline":"Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)"}, {"id":142914178,"url":"https://finnhub.io/api/news?id=9b328f3a9cf99637ab5347e872d1909f863d081eb03e438f7e2ad16fa8f84749","image":"","source":"SeekingAlpha","related":"BIIB","summary":"","category":"company","datetime":1792053514,"headline":"Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform"}, {"id":142848926,"url":"https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.","category":"company","datetime":1791896520,"headline":"Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"}, {"id":142852675,"url":"https://finnhub.io/api/news?id=af92692e7d4eb3fa802ba818f7325fb8bdd1ff0aa1fa76b8095a64770bb2fa39","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen is set to report its Q3 results soon, with analysts expecting a sharp double-digit decline in EPS.","category":"company","datetime":1791889186,"headline":"Biogen’s Quarterly Earnings Preview: What You Need to Know"}, {"id":142827405,"url":"https://finnhub.io/api/news?id=c51779d3d7df77a8032713ac011bce19574478f7f4bfa06d8b2b04781d1ee56c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]","category":"company","datetime":1791851470,"headline":"Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?"}, {"id":142825321,"url":"https://finnhub.io/api/news?id=db2d71f668cfe165e13f89cb01429985e98f0c46c6e9c5d7c7e8c751d51658d0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210.","category":"company","datetime":1791846183,"headline":"Biogen (BIIB) Stock Is Up, What You Need To Know"}, {"id":142825643,"url":"https://finnhub.io/api/news?id=2475f1deb3835cbd3a0765fb299f01eb86bba1652dad585ca19f2fb448e6f863","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or potential buyer: Is the current share price aligned with what the business may realistically produce in cash over time, based on its existing drugs and pipeline investments? Over the past 12 months Biogen has delivered a 58.6% share price gain, which raises the stakes on whether the recent momentum is fully grounded in its future cash...","category":"company","datetime":1791843422,"headline":"Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom"}, {"id":142824661,"url":"https://finnhub.io/api/news?id=5c5da9a40564805d54d1dc343a21338d71aaf0825323ce7c37fed45388edb71c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen Inc. recently reported 52-week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, showing sustained improvements in skin disease activity and a generally well tolerated safety profile in patients who had not responded to or tolerated standard antimalarial therapies. The extended data, supported by the FDA’s Breakthrough Therapy Designation for litifilimab in CLE, reinforce its potential as a first-in-class, once-monthly therapy targeting BDCA2 on...","category":"company","datetime":1791839401,"headline":"What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders"}, {"id":142823670,"url":"https://finnhub.io/api/news?id=5fcf98e656cace331f2453ea7672ef37921d4739c8dd76fe6128164881780509","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He","category":"company","datetime":1791834672,"headline":"Sector Update: Healthcare Stocks Rise Late Afternoon"}, {"id":142823832,"url":"https://finnhub.io/api/news?id=677e3129c524cac7324c3c367bb91446ce3bb59dfccd4015298516546df7e2f4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For investors, the litifilimab update comes after a solid run in the Biogen share price, with a 90 day share price return of 17.6% and a year-to-date share price gain of 26.9%. The 1 year total shareholder return of 56.0% contrasts with declines over the 3 and 5...","category":"company","datetime":1791832278,"headline":"Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data"}, {"id":142823403,"url":"https://finnhub.io/api/news?id=7d346a60f670e8f9ddc8279296e8c4fd9cae67d242e655a952cce9bcd63808f9","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"BIIB","summary":"Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.","category":"company","datetime":1791831901,"headline":"Discover which S&P500 stocks are making waves on Monday."}, {"id":142823673,"url":"https://finnhub.io/api/news?id=d7b89a9724b6684eca2328ec43aa70627caa9eab7fbe881eb5a41bc920aa007e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.","category":"company","datetime":1791825300,"headline":"Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%."}, {"id":142822704,"url":"https://finnhub.io/api/news?id=24b33c08cf2e4246cd25e93cfa18caf87d1874dbf16960dd270daf649b1c0ae0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.","category":"company","datetime":1791823020,"headline":"Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning."}, {"id":139933529,"url":"https://finnhub.io/api/news?id=3f89e8879d586e5cd629005d198da398df5b90ad7a78af13079c92adb0c779d5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls","category":"company","datetime":1791812513,"headline":"Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls"}, {"id":142819368,"url":"https://finnhub.io/api/news?id=07790595272c5552eeb9761d5fde2990c182b228c2dfe7de944815e11443ca2d","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"BIIB","summary":"Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.","category":"company","datetime":1791808501,"headline":"Stay updated with the S&P500 stocks that are on the move in today's pre-market session."}, {"id":142819942,"url":"https://finnhub.io/api/news?id=07f905e4227277833637cc9692fb32fd055a9623d4c589916ec427d9029892db","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Big banks kick off third-quarter earnings season tomorrow, and Wall Street analysts are already reshuffling their bets with a wave of surprise upgrades, downgrades, and fresh initiations across some of the market's most closely watched names.","category":"company","datetime":1791807288,"headline":"Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More"}, {"id":142819091,"url":"https://finnhub.io/api/news?id=471dbe8e44ee052eb30f6c569e370934be3284f5b7ba0d58c5ba598bcbe43d12","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Investing.com -- JPMorgan lifted its rating for Biogen to Overweight from Neutral on Monday, pointing to a stronger run of clinical catalysts in 2027 and an improved long-term growth outlook.","category":"company","datetime":1791805893,"headline":"JPMorgan gets bullish on Biogen ahead of 2027 catalysts"}, {"id":142819094,"url":"https://finnhub.io/api/news?id=197cda554926ff4bffb812a468f6f11289dc392b1557e6f58842bb3211238b12","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.","category":"company","datetime":1791804818,"headline":"BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300"}, {"id":142818618,"url":"https://finnhub.io/api/news?id=bf55334356bfe7e1144b5fcce0e6e447dc280a1bcb47e2c450075116711cad84","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.","category":"company","datetime":1791803943,"headline":"2 Surging Stocks for Long-Term Investors and 1 We Brush Off"}, {"id":142821118,"url":"https://finnhub.io/api/news?id=9f18d7df53934337e115b97a5d65f47d70dca4bebe046ca327085a633ed5600c","image":"","source":"Benzinga","related":"BIIB","summary":"JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.","category":"company","datetime":1791792520,"headline":"JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300"}, {"id":142822417,"url":"https://finnhub.io/api/news?id=a47529ceee0ab307e354aa282be6ff31574e4c12c718fdc96327ce61026e1cee","image":"https://image.cnbcfm.com/api/v1/image/108353411-1787591101647-gettyimages-2271704570-US_STOCKS.jpeg?v=1791803914&w=1920&h=1080","source":"CNBC","related":"BIIB","summary":"These are the stocks posting the largest moves in early trading.","category":"company","datetime":1791790494,"headline":"Stocks making the biggest moves premarket: Salesforce, First Solar, Biogen & more"}, {"id":142791726,"url":"https://finnhub.io/api/news?id=9b65622705e3e362c7d28e05ef0dad0df47d77c3014d499293dee044acee525e","image":"","source":"Benzinga","related":"BIIB","summary":"UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $240 to $270.","category":"company","datetime":1791545871,"headline":"UBS Maintains Buy on Biogen, Raises Price Target to $270"}, {"id":142761821,"url":"https://finnhub.io/api/news?id=4d18da8f83cbf10d03b8e55007e78b17505bf058240a9eaa589964cca136f7d0","image":"","source":"Benzinga","related":"BIIB","summary":"RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.","category":"company","datetime":1791453637,"headline":"RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256"}, {"id":142694288,"url":"https://finnhub.io/api/news?id=bcf3d87d4790c76efdb9f81b82b264678fd2118cba6bdac7427e6d2884743781","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1687462580/image_1687462580.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BIIB","summary":"Seeking Alpha welcomed 38 new analysts in September 2026. Read more on companies Qualcomm, Teladoc, and NewLake Capital Partners, as well as the TDAQ ETF here.","category":"company","datetime":1791363600,"headline":"Stock Picks From Seeking Alpha's September 2026 New Analysts"}, {"id":142667876,"url":"https://finnhub.io/api/news?id=590d600038e76549d58cef880a58e000fde6a8bfa4d2054dc0ba7825564c1b97","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development...","category":"company","datetime":1791306360,"headline":"Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says"}, {"id":142667005,"url":"https://finnhub.io/api/news?id=48f11ac08d54b3e28cde258398358b2925e7aa8f85da3dab2e94259b8cf24501","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.","category":"company","datetime":1791299406,"headline":"Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?"}, {"id":142662624,"url":"https://finnhub.io/api/news?id=dad5fb9983d775cad72c5c2338c949078af0797bb8002c1c8c00ef248e80b39b","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536","source":"Benzinga","related":"BIIB","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often","category":"company","datetime":1791207317,"headline":"4 Health Care Stocks With Whale Alerts In Today’s Session"}, {"id":142623734,"url":"https://finnhub.io/api/news?id=5ef42e365d061cd004b39da4a3381f1dc657230a05e8d5dfce4caff85682c00e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2297903713/image_2297903713.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BIIB","summary":"Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.","category":"company","datetime":1791108485,"headline":"Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027"}, {"id":142591079,"url":"https://finnhub.io/api/news?id=3df0e72a2c6efea5ebc369c53b29a52821681a3ceabab71ef718925082530046","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started","category":"company","datetime":1790954400,"headline":"Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus"}, {"id":142590792,"url":"https://finnhub.io/api/news?id=510ff0cf1c37661401ef523a1a0e96744fe98ab89cc4cc962cc7fdea3fb87a06","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.","category":"company","datetime":1790946000,"headline":"Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?"}, {"id":142614572,"url":"https://finnhub.io/api/news?id=c23deb453532ed87d821a806f371c227f93b0b12402bf0229ca8ec0e427ca878","image":"","source":"Benzinga","related":"BIIB","summary":"Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated","category":"company","datetime":1790940387,"headline":"Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated"}, {"id":142556747,"url":"https://finnhub.io/api/news?id=630adcfe3e0f85eada15d3e2b89c416d5339bdaebbf0eeb9bed4bcd20e1ce5ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.","category":"company","datetime":1790854867,"headline":"1 Profitable Stock Worth Investigating and 2 We Ignore"}, {"id":142554444,"url":"https://finnhub.io/api/news?id=bece47a1e8fdf58a8f0d6edbe5160ce9e0d5db69bc8bd497806f738745132545","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the \"Board\"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.","category":"company","datetime":1790852400,"headline":"HLS Therapeutics Announces Board of Directors Changes"}, {"id":142476966,"url":"https://finnhub.io/api/news?id=e56065f8d8bb86d533d9eb5479d567e55420ae19d538b5fd5211f4c034ab3811","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.","category":"company","datetime":1790655819,"headline":"Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?"}, {"id":142468171,"url":"https://finnhub.io/api/news?id=0ffd656afbd32cbc60aff049296e4e6619a3faa131c3e4caa1bbd4259fd96270","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BIIB","summary":"BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.","category":"company","datetime":1790602860,"headline":"Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 4
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 82
discarded_article_count 63
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.3 5/110 46% 2.3
資金流 13.2 20/110 66% 13.2
市場環境 11.8 15/110 78.67% 11.8
催化劑 6 20/110 30% 6
風險管理 6.5 10/110 65% 6.5
技術信號 20.2 30/110 67.33% 20.2
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 17/50
ret_5d 0.0127
max_score 50
max_total 50
raw_total 17
vcp_bonus 0
vol_ratio 1.7886
ret_points 4
vol_points 6
range_ratio 2.3518
volat_points 4
day_range_pct 0.0639
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.3

details

atrPct 3.264
turnoverUsdM 567.3469
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.BIIB
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 228.1186

strength_details

ma_score 1.5
atr_score 1
rsi_score 0.5
macd_score 3
volume_score 2
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 6.5
take_profit_price 261.2028
target_multiplier 1.9
technical_strength 1.7
take_profit_percent 7
positionPoints 1.3
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 6.5279
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.3/5分
資金流分析總分: 13.2/20分
市場環境分析總分: 11.8/15分
催化劑分析: 6/20分
風險管理總分: 6.5/10分
技術信號分析總分: 20.2/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 85.71
atr
atr 7.9657
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.26
cci
rule Cursor_18.24 CCI bands
level 強勢區
score 10
value 98.26
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.1133
kdj
d 81.69
j 62.97
k 75.45
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 入貨中
score 8
value 63.32
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 8
trend 資金入貨
value 2823684
recentSlope 127418.4
previousSlope 127330
rsi
value 71.37
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 231.1614
position SAR喺價下
distancePct 5.28
previousTrend 上升
ma50
value 225.731
macd
macd 7.5691
trend 強烈看漲
signal 6.1618
histogram 1.4073
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 235.7299
position 連續5日>VWAP
consecutiveAbove 14
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.74
score 6
avgVolume 1338321
currentVolume 2324716
derived
ma20 234.287
ma50 225.731
prevClose 252.73
avgVolume10 1436182
avgVolume20 1338321
changePercent -3.43
avgVolumeForScore 1338321
ma_cross
ma20 234.287
ma50 225.731
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 233.3785
prevMa50 225.101
spreadPct 3.79
isVolumeBreakout true
bollinger
lower 211.2765
upper 257.2975
position 上半部
rsi_short
value 51.65
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.74

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.2639622626843403,
        "turnoverUsdM": 567.346946774148,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 228.1186,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 6.5,
      "take_profit_price": 261.2028,
      "target_multiplier": 1.9,
      "technical_strength": 1.7,
      "take_profit_percent": 7
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.527924525368681,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 83,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 66,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 234.287,
    "ma50": 225.731,
    "close": 244.05,
    "prevClose": 252.73,
    "avgVolume20": 1338321,
    "volumeRatio": 1.74,
    "changePercent": -3.43
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.012739658892854333,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 0,
      "vol_ratio": 1.7885870359684555,
      "ret_points": 4,
      "vol_points": 6,
      "range_ratio": 2.351756348794325,
      "volat_points": 4,
      "day_range_pct": 0.06392133090856791,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 83,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 11.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 78.67,
        "contribution": 11.8
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 20.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67.33,
        "contribution": 20.2
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "謹慎買入",
    "result": 66,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 11.8/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 20.2/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.3,
      "資金流": 13.2,
      "市場環境": 11.8,
      "情緒分析": 6,
      "技術信號": 20.2,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.3,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 567.346946774148,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 3.2,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 17.52
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 732.47650135,
                "ma50": 725.4243990000001,
                "name": "QQQ",
                "close": 725.60999,
                "points": 1.4
              },
              "spy": {
                "ma20": 770.8954959000001,
                "ma50": 767.6259946999999,
                "name": "SPY",
                "close": 772.31,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.2639622626843403,
          "atrPoints": 2,
          "cciPoints": 4,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143261009,
                "url": "https://finnhub.io/api/news?id=3f10b0470f74ce88e789b68777ecd0afd9b8e3b684a5b3f44301080da48a2754",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Growth portfolio revenue jumped 49%, now 63% of core pharma sales.",
                "category": "company",
                "datetime": 1793207624,
                "headline": "Biogen (BIIB) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 143261010,
                "url": "https://finnhub.io/api/news?id=e40ac030393c1087fc34195b0c8660b2063a0cd4ccf2116169c4ab1c56573ca6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.",
                "category": "company",
                "datetime": 1793203860,
                "headline": "BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened"
              },
              {
                "id": 143262321,
                "url": "https://finnhub.io/api/news?id=c072351f36fb2ad19734be7692214840661ef52fadc9a3fbde57aefc2d310b7a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
                "category": "company",
                "datetime": 1793203257,
                "headline": "Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 143256768,
                "url": "https://finnhub.io/api/news?id=e66c2cd6a9105bce9ed6d616829743f8e15944612f425b4c3f19a7358be3f369",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1793190604,
                "headline": "Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates"
              },
              {
                "id": 143256767,
                "url": "https://finnhub.io/api/news?id=c9f1f0c65d832b0c1eee004a85a679e6e18b4ce44f8f13719a96bf346b5c887e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 2026, with revenue up 10.6% year on year to $2.80 billion. Its non-GAAP profit of $2.62 per share was 32.5% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1793188492,
                "headline": "Biogen (NASDAQ:BIIB) delivers impressive Q3 2026"
              },
              {
                "id": 143254954,
                "url": "https://finnhub.io/api/news?id=a9f487a9153087d8f8f9ec394803ef83663db960aeece8806438536530b918ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1793184602,
                "headline": "Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates"
              },
              {
                "id": 143237260,
                "url": "https://finnhub.io/api/news?id=120089cfdff5c5eecf5106ab5470c0912020cdfba5a9dcccf6d46644b9621bc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) heads into a key moment this week, with the biotech group set to report quarterly earnings before the market opens on Wednesday, a focal point for current sentiment. Recent price action has been strong. Biogen’s 1 day share price return of 0.63% and 7 day share price return of 8.04% contribute to a 90 day share price return of 22.69%, with total shareholder return over the past year at 67.69%. This suggests that optimism around upcoming catalysts and recent product updates is...",
                "category": "company",
                "datetime": 1793110147,
                "headline": "Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued"
              },
              {
                "id": 143234677,
                "url": "https://finnhub.io/api/news?id=67b92752082a6fb569388db66a39d75b3effb46d8721b147d1999fd96c60b4e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has delivered a strong run over the past year, and the key issue for you now is whether the current share price lines up with the cash the business is expected to generate. After a move like this, the question is how much of Biogen’s future cash flows the market may already be pricing in. Biogen has returned 67.7% over the past year, which puts real pressure on the question of whether recent gains are fully supported by its underlying cash flow potential. Fresh data around EMPAVELI...",
                "category": "company",
                "datetime": 1793107171,
                "headline": "Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data"
              }
            ],
            "raw_source": [
              {
                "id": 143260586,
                "url": "https://finnhub.io/api/news?id=1d79ccf6f3610d78e9ad26a2d47e9c6c688db90116702300cf2bf2daf22ade2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Moby summary of Biogen Inc.'s Q3 2026 earnings call",
                "category": "company",
                "datetime": 1793208637,
                "headline": "Biogen Inc. Q3 2026 Earnings Call Summary"
              },
              {
                "id": 143261009,
                "url": "https://finnhub.io/api/news?id=3f10b0470f74ce88e789b68777ecd0afd9b8e3b684a5b3f44301080da48a2754",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Growth portfolio revenue jumped 49%, now 63% of core pharma sales.",
                "category": "company",
                "datetime": 1793207624,
                "headline": "Biogen (BIIB) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 143261010,
                "url": "https://finnhub.io/api/news?id=e40ac030393c1087fc34195b0c8660b2063a0cd4ccf2116169c4ab1c56573ca6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.",
                "category": "company",
                "datetime": 1793203860,
                "headline": "BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened"
              },
              {
                "id": 143262321,
                "url": "https://finnhub.io/api/news?id=c072351f36fb2ad19734be7692214840661ef52fadc9a3fbde57aefc2d310b7a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
                "category": "company",
                "datetime": 1793203257,
                "headline": "Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 143261583,
                "url": "https://finnhub.io/api/news?id=380d9e75595ab13a3f271bbc2186e20d8075d57c1b72abeef50205567640dcb0",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "2026-10-28. The following slide deck was published by Biogen Inc.",
                "category": "company",
                "datetime": 1793199677,
                "headline": "Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation"
              },
              {
                "id": 143259457,
                "url": "https://finnhub.io/api/news?id=3a1980846c6a2a79477968f0e6ee7d6538d2b01af709a304ad78345d5af52984",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) reported third-quarter 2026 earnings and revenue above analyst expectations on Wednesday, supported by growth across its newer treatments and the first full-quarter contribution from products acquired through its purchase of Apellis in May.",
                "category": "company",
                "datetime": 1793195630,
                "headline": "Biogen Q3 Earnings Beat Estimates as Revenue Rises 11% and 2026 Profit Guidance Improves"
              },
              {
                "id": 143259229,
                "url": "https://finnhub.io/api/news?id=0a31c4aa1e295543824d9a80799ce3fe05c4bc1fa5a93677f625a2f9369b7390",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "We have a solid slate of reports today, both of the earnings variety and regarding economic growth.",
                "category": "company",
                "datetime": 1793194680,
                "headline": "Big Day for Econ Data, Hyperscaler Earnings"
              },
              {
                "id": 143259051,
                "url": "https://finnhub.io/api/news?id=f09e9eb855f9f12cb39e161fded1b77da23237f9492fc38b04074ece9e249dd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.",
                "category": "company",
                "datetime": 1793194380,
                "headline": "How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?"
              },
              {
                "id": 143256768,
                "url": "https://finnhub.io/api/news?id=e66c2cd6a9105bce9ed6d616829743f8e15944612f425b4c3f19a7358be3f369",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1793190604,
                "headline": "Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates"
              },
              {
                "id": 143256766,
                "url": "https://finnhub.io/api/news?id=37dbfb4e6b1e3661246a09d898a581825e6492934194bfc57b2d868b43fc5dd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "If Biogen sat on your watchlist instead of in your portfolio over the past year, the result may feel like a missed shot. Investors who held Biogen over the past year are up 69.5%, including dividends. That outcome sits against a backdrop where analysts in late 2025 were split on whether shrinking revenue, higher margins, and a 3-year P/E reset could work. Which of those business assumptions would you focus on if you were making that call again today? Narratives are how investors here put a...",
                "category": "company",
                "datetime": 1793189598,
                "headline": "What Biogen Doubters Overlooked"
              },
              {
                "id": 143256767,
                "url": "https://finnhub.io/api/news?id=c9f1f0c65d832b0c1eee004a85a679e6e18b4ce44f8f13719a96bf346b5c887e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 2026, with revenue up 10.6% year on year to $2.80 billion. Its non-GAAP profit of $2.62 per share was 32.5% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1793188492,
                "headline": "Biogen (NASDAQ:BIIB) delivers impressive Q3 2026"
              },
              {
                "id": 143254954,
                "url": "https://finnhub.io/api/news?id=a9f487a9153087d8f8f9ec394803ef83663db960aeece8806438536530b918ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1793184602,
                "headline": "Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates"
              },
              {
                "id": 143254955,
                "url": "https://finnhub.io/api/news?id=bc71f6f78a47ab607cf5b627b41d4ba7c540ced449d93c9193534eba439aeab3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Biogen Inc (NASDAQ:BIIB) on Wednesday reported third quarter adjusted earnings per share of $2.62, surpassing the analyst consensus of $2.02 by $0.60. Revenue reached $2.8 billion, exceeding the $2.64 billion estimate and representing an 11% increase from the prior year period.",
                "category": "company",
                "datetime": 1793184288,
                "headline": "Biogen beats Q3 estimates, raises guidance floor on growth"
              },
              {
                "id": 143254958,
                "url": "https://finnhub.io/api/news?id=1f7c7197ef94647283f364a62f59fdf57b39d74fdce077fb4203a1ec373cf82e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 32.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 203.8 million, which is an increase of approximately 74 percent compared to the royalty recorded by BioArctic for the third quarter of 2025.",
                "category": "company",
                "datetime": 1793183220,
                "headline": "Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026"
              },
              {
                "id": 143254956,
                "url": "https://finnhub.io/api/news?id=888827508cb920e674aa339923ad30e549d82cbdad45cf9fd064f6dbf91fe2b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance boost.",
                "category": "company",
                "datetime": 1793182287,
                "headline": "Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report"
              },
              {
                "id": 143254957,
                "url": "https://finnhub.io/api/news?id=6d39fdd58057f30a155224114223705b28c4566931152024475047c19ad94c70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.",
                "category": "company",
                "datetime": 1793181660,
                "headline": "Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack."
              },
              {
                "id": 143258376,
                "url": "https://finnhub.io/api/news?id=a5bae5e39fc2b4daf81ddcb0240db5f6c5ba5c20079563cc74e7dff5d95e1380",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/28/Stock-market-chart-with-green-candlestic.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For",
                "category": "company",
                "datetime": 1793180793,
                "headline": "Biogen Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 143258377,
                "url": "https://finnhub.io/api/news?id=b511fe2d632727e3e2f35a35ff3ae506da4f1c83ecd499126e645912886e9662",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "- Conference Call",
                "category": "company",
                "datetime": 1793177147,
                "headline": "Biogen Exec Expects Growth From Apellis Acquisition Even Without The Pipeline"
              },
              {
                "id": 143258378,
                "url": "https://finnhub.io/api/news?id=ab28e1c0a340a8e906c10614d797de84d929fc8062f2b0acc9ad1726439de942",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "https://event.webcasts.com/viewer/event.jsp?ei=1771787&tp_key=52bcd10df0",
                "category": "company",
                "datetime": 1793176933,
                "headline": "Biogen Exec Says Expecting Growth From Apellis Acquisition Even Without The Pipeline; Our Ambition Is Over The Next Few Years To Have At Least 20 Programs In Early Stage Development"
              },
              {
                "id": 143258379,
                "url": "https://finnhub.io/api/news?id=a3c51f910ea089c6594ee53ae8779640cf42d322ff46fda27d60b35946fe468e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) narrows FY2026 Adj EPS guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 analyst estimate..",
                "category": "company",
                "datetime": 1793167612,
                "headline": "CORRECTION: Biogen Narrows FY2026 Adj EPS Guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 Est"
              },
              {
                "id": 143258380,
                "url": "https://finnhub.io/api/news?id=9e8e519ee3ff9f88eed98e5e0b662e3c734d10ffa6be358d7e755788addc94d1",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $12.20-$13.00 vs $12.36 analyst estimate..",
                "category": "company",
                "datetime": 1793167327,
                "headline": "Biogen Raises FY2026 GAAP EPS Guidance from $12.00-$13.00 to $12.20-$13.00 vs $5.84 Est"
              },
              {
                "id": 143237260,
                "url": "https://finnhub.io/api/news?id=120089cfdff5c5eecf5106ab5470c0912020cdfba5a9dcccf6d46644b9621bc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) heads into a key moment this week, with the biotech group set to report quarterly earnings before the market opens on Wednesday, a focal point for current sentiment. Recent price action has been strong. Biogen’s 1 day share price return of 0.63% and 7 day share price return of 8.04% contribute to a 90 day share price return of 22.69%, with total shareholder return over the past year at 67.69%. This suggests that optimism around upcoming catalysts and recent product updates is...",
                "category": "company",
                "datetime": 1793110147,
                "headline": "Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued"
              },
              {
                "id": 143234677,
                "url": "https://finnhub.io/api/news?id=67b92752082a6fb569388db66a39d75b3effb46d8721b147d1999fd96c60b4e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has delivered a strong run over the past year, and the key issue for you now is whether the current share price lines up with the cash the business is expected to generate. After a move like this, the question is how much of Biogen’s future cash flows the market may already be pricing in. Biogen has returned 67.7% over the past year, which puts real pressure on the question of whether recent gains are fully supported by its underlying cash flow potential. Fresh data around EMPAVELI...",
                "category": "company",
                "datetime": 1793107171,
                "headline": "Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data"
              },
              {
                "id": 143233087,
                "url": "https://finnhub.io/api/news?id=74aab667e93c48b17302c90a31f34ca9928c6d3a47a5857ea90b05480fafc1a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Wednesday before market open. Here’s what to look for.",
                "category": "company",
                "datetime": 1793096567,
                "headline": "Biogen earnings: what to look for from BIIB"
              },
              {
                "id": 143204994,
                "url": "https://finnhub.io/api/news?id=66f63e0574940212ee3b29263edc38410fe307dec9128ccd68e63f19c8dbce9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Kos Biotechnology Partners (\"Kos\"), a global life sciences investment firm bridging the U.S. and European biopharma ecosystems, today announced a strategic investment in Golden Age Health (GAH) through its inaugural fund, Kos BioVentures. As part of this partnership, Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners, will join the Golden Age Health Board of Directors.",
                "category": "company",
                "datetime": 1793052180,
                "headline": "Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies"
              },
              {
                "id": 143202832,
                "url": "https://finnhub.io/api/news?id=7b8c988faaf29be1070f93a78eba578a30276fb5ea8f0464c621319420abd6f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.",
                "category": "company",
                "datetime": 1793042220,
                "headline": "Corxel, an obesity drugmaker, to go public via SPAC deal"
              },
              {
                "id": 143197963,
                "url": "https://finnhub.io/api/news?id=16a7bc6d08aceeea8f390458bad4f92e66e9dfc2d8069874e0beca1b6575ad2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.",
                "category": "company",
                "datetime": 1793018280,
                "headline": "Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?"
              },
              {
                "id": 143191497,
                "url": "https://finnhub.io/api/news?id=f113f7c826dfccdc8930bdf4db309c7b85cb6fbb111034d7b4c7ec7809e2cc0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792998707,
                "headline": "Can Corcept Therapeutics Stock Rally 40% After This Dip?"
              },
              {
                "id": 143191625,
                "url": "https://finnhub.io/api/news?id=f488331be4fc0aabb6b91d631958c54c2e6eedde32af3d9e4b889a6a1c65305b",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "",
                "category": "company",
                "datetime": 1792987500,
                "headline": "Baron Health Care Fund: Q3 2026 New Positions And Exits"
              },
              {
                "id": 143132469,
                "url": "https://finnhub.io/api/news?id=8d7c4734f1737893dbcd9e02eb809a58ba77d9c2c5f439008bb8400a9de59eb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "category": "company",
                "datetime": 1792750740,
                "headline": "Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?"
              },
              {
                "id": 143104128,
                "url": "https://finnhub.io/api/news?id=2b8d6979c1a213c87a4ba1f8a01170b9797ae35df10f79cd3d6a38a120ede13f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Key TakeawaysBiogen shares rose 5% today after BofA raised its price target to $244 from $219 and kept a Neutral rating. BofA’s new target is close to the $247 consensus target, which has climbed 43% over the past year as analysts try to keep up with the stock.",
                "category": "company",
                "datetime": 1792702326,
                "headline": "Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3"
              },
              {
                "id": 143102773,
                "url": "https://finnhub.io/api/news?id=0a2a907a5898714f245153f9c44f38d24520e82c941a5134ed19de6477214e44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792674009,
                "headline": "Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"
              },
              {
                "id": 143101191,
                "url": "https://finnhub.io/api/news?id=77cc35f119852aa14aa59bb6baea57ab8b24608570e9b377887056e484594750",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "B of A Securities  analyst Jason Zemansky   maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.",
                "category": "company",
                "datetime": 1792654702,
                "headline": "B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244"
              },
              {
                "id": 143070296,
                "url": "https://finnhub.io/api/news?id=ddc6e1144b1bd498cc2fca211d0682d66fc2d11daddebb95133578b52647a3d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792587618,
                "headline": "Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release"
              },
              {
                "id": 143067862,
                "url": "https://finnhub.io/api/news?id=84a790847668ebb238e90facc3949ebb837ce3c4520939792a11d2dcc6cf93b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.",
                "category": "company",
                "datetime": 1792584360,
                "headline": "The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics"
              },
              {
                "id": 143069839,
                "url": "https://finnhub.io/api/news?id=46c5a51c20d04bf20555bdeae73e41626773be092b9cb0aaba68f1c80fc4748b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254102883/image_2254102883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock here.",
                "category": "company",
                "datetime": 1792582262,
                "headline": "Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm"
              },
              {
                "id": 143069179,
                "url": "https://finnhub.io/api/news?id=4268518ed28f3e77559414e68b7f1071953c46e77bf731c62334a41314eee89f",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.",
                "category": "company",
                "datetime": 1792576437,
                "headline": "TD Cowen Maintains Buy on Biogen, Raises Price Target to $250"
              },
              {
                "id": 143031147,
                "url": "https://finnhub.io/api/news?id=644dd6ec18767427693e2fe0f20c8e8cc753f3fb6de07218e5f1d48be6f44f23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head of Equity Strategy Lori Calvasina noted that Healthcare historically moves inversely to Technology’s relative performance versus the S&P 500, making it a natural destination when r",
                "category": "company",
                "datetime": 1792524424,
                "headline": "RBC Capital names top healthcare stocks as sector upgraded to overweight"
              },
              {
                "id": 143031680,
                "url": "https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.",
                "category": "company",
                "datetime": 1792514161,
                "headline": "S&P 500 Top Movers: Gainers and Losers From Today's US Session"
              },
              {
                "id": 143029159,
                "url": "https://finnhub.io/api/news?id=f479ad2df5936d859f53f8c84a798333a56d9d576d6101676e3408d578046dc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.",
                "category": "company",
                "datetime": 1792503000,
                "headline": "4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now"
              },
              {
                "id": 143025571,
                "url": "https://finnhub.io/api/news?id=3bad8a224e7ed91550e1b91d6b1e29ab595863dc9bd082ea62f67e3e3620a61a",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.",
                "category": "company",
                "datetime": 1792490147,
                "headline": "Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310"
              },
              {
                "id": 143006658,
                "url": "https://finnhub.io/api/news?id=128f392596d085f3a087a2d4ba623a478b80c0f19e3bbeaab0568482cbae6a3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.",
                "category": "company",
                "datetime": 1792411200,
                "headline": "AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results"
              },
              {
                "id": 143005875,
                "url": "https://finnhub.io/api/news?id=4ee66815d7416467592281892f43dbf5a66333fe7e9a275b9718728c2bd720d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured CAMBRIDGE",
                "category": "company",
                "datetime": 1792409400,
                "headline": "Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week"
              },
              {
                "id": 143006438,
                "url": "https://finnhub.io/api/news?id=d54e48dd82215b7c03c46d22f4fb67787dc5f58177306ba2eae9c9a7c5e50530",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of",
                "category": "company",
                "datetime": 1792395141,
                "headline": "Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week"
              },
              {
                "id": 142954484,
                "url": "https://finnhub.io/api/news?id=566b777de47cf4258a817a60d513bcb7ddc7645f2b14d60abe037a9814ff7172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "JPMorgan strongly reset its price target on the company’s attractive 2027 pipeline catalysts.",
                "category": "company",
                "datetime": 1792197420,
                "headline": "A kidney transplant milestone has Wall Street excited about Biogen"
              },
              {
                "id": 142950200,
                "url": "https://finnhub.io/api/news?id=b1fa0d753cf23ca6d1367c84b71f611b5973b1c128e237773dd2d8fd0e33782a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "It's another risk-off day for the broader market, with tech taking another tumble, thanks to a continued slide for semiconductor stocks.",
                "category": "company",
                "datetime": 1792172809,
                "headline": "Another Biotech IPO Pops on Rough Day for Broader Market"
              },
              {
                "id": 142944427,
                "url": "https://finnhub.io/api/news?id=9d0c8c9629cbfe7d9c78c8a89266ac9138c21201484802bea94c0a2c6af6bdc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as \"ADPKD.\"",
                "category": "company",
                "datetime": 1792146600,
                "headline": "Biogen-backed Estuary nabs $93M for kidney disease gene therapy"
              },
              {
                "id": 142944885,
                "url": "https://finnhub.io/api/news?id=f91f403f3ffc3a12e9d0386f0f23990216287021ab63ad0404ebea0e9b7ed963",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimer’s revenue growth, and key risk/reward drivers—read now. Click for this BIIB update.",
                "category": "company",
                "datetime": 1792139325,
                "headline": "Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)"
              },
              {
                "id": 142914178,
                "url": "https://finnhub.io/api/news?id=9b328f3a9cf99637ab5347e872d1909f863d081eb03e438f7e2ad16fa8f84749",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "",
                "category": "company",
                "datetime": 1792053514,
                "headline": "Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform"
              },
              {
                "id": 142848926,
                "url": "https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.",
                "category": "company",
                "datetime": 1791896520,
                "headline": "Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"
              },
              {
                "id": 142852675,
                "url": "https://finnhub.io/api/news?id=af92692e7d4eb3fa802ba818f7325fb8bdd1ff0aa1fa76b8095a64770bb2fa39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is set to report its Q3 results soon, with analysts expecting a sharp double-digit decline in EPS.",
                "category": "company",
                "datetime": 1791889186,
                "headline": "Biogen’s Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 142827405,
                "url": "https://finnhub.io/api/news?id=c51779d3d7df77a8032713ac011bce19574478f7f4bfa06d8b2b04781d1ee56c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]",
                "category": "company",
                "datetime": 1791851470,
                "headline": "Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?"
              },
              {
                "id": 142825321,
                "url": "https://finnhub.io/api/news?id=db2d71f668cfe165e13f89cb01429985e98f0c46c6e9c5d7c7e8c751d51658d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210.",
                "category": "company",
                "datetime": 1791846183,
                "headline": "Biogen (BIIB) Stock Is Up, What You Need To Know"
              },
              {
                "id": 142825643,
                "url": "https://finnhub.io/api/news?id=2475f1deb3835cbd3a0765fb299f01eb86bba1652dad585ca19f2fb448e6f863",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or potential buyer: Is the current share price aligned with what the business may realistically produce in cash over time, based on its existing drugs and pipeline investments? Over the past 12 months Biogen has delivered a 58.6% share price gain, which raises the stakes on whether the recent momentum is fully grounded in its future cash...",
                "category": "company",
                "datetime": 1791843422,
                "headline": "Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom"
              },
              {
                "id": 142824661,
                "url": "https://finnhub.io/api/news?id=5c5da9a40564805d54d1dc343a21338d71aaf0825323ce7c37fed45388edb71c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. recently reported 52-week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, showing sustained improvements in skin disease activity and a generally well tolerated safety profile in patients who had not responded to or tolerated standard antimalarial therapies. The extended data, supported by the FDA’s Breakthrough Therapy Designation for litifilimab in CLE, reinforce its potential as a first-in-class, once-monthly therapy targeting BDCA2 on...",
                "category": "company",
                "datetime": 1791839401,
                "headline": "What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders"
              },
              {
                "id": 142823670,
                "url": "https://finnhub.io/api/news?id=5fcf98e656cace331f2453ea7672ef37921d4739c8dd76fe6128164881780509",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He",
                "category": "company",
                "datetime": 1791834672,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 142823832,
                "url": "https://finnhub.io/api/news?id=677e3129c524cac7324c3c367bb91446ce3bb59dfccd4015298516546df7e2f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For investors, the litifilimab update comes after a solid run in the Biogen share price, with a 90 day share price return of 17.6% and a year-to-date share price gain of 26.9%. The 1 year total shareholder return of 56.0% contrasts with declines over the 3 and 5...",
                "category": "company",
                "datetime": 1791832278,
                "headline": "Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data"
              },
              {
                "id": 142823403,
                "url": "https://finnhub.io/api/news?id=7d346a60f670e8f9ddc8279296e8c4fd9cae67d242e655a952cce9bcd63808f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791831901,
                "headline": "Discover which S&P500 stocks are making waves on Monday."
              },
              {
                "id": 142823673,
                "url": "https://finnhub.io/api/news?id=d7b89a9724b6684eca2328ec43aa70627caa9eab7fbe881eb5a41bc920aa007e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.",
                "category": "company",
                "datetime": 1791825300,
                "headline": "Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%."
              },
              {
                "id": 142822704,
                "url": "https://finnhub.io/api/news?id=24b33c08cf2e4246cd25e93cfa18caf87d1874dbf16960dd270daf649b1c0ae0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.",
                "category": "company",
                "datetime": 1791823020,
                "headline": "Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning."
              },
              {
                "id": 139933529,
                "url": "https://finnhub.io/api/news?id=3f89e8879d586e5cd629005d198da398df5b90ad7a78af13079c92adb0c779d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1791812513,
                "headline": "Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls"
              },
              {
                "id": 142819368,
                "url": "https://finnhub.io/api/news?id=07790595272c5552eeb9761d5fde2990c182b228c2dfe7de944815e11443ca2d",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.",
                "category": "company",
                "datetime": 1791808501,
                "headline": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session."
              },
              {
                "id": 142819942,
                "url": "https://finnhub.io/api/news?id=07f905e4227277833637cc9692fb32fd055a9623d4c589916ec427d9029892db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Big banks kick off third-quarter earnings season tomorrow, and Wall Street analysts are already reshuffling their bets with a wave of surprise upgrades, downgrades, and fresh initiations across some of the market's most closely watched names.",
                "category": "company",
                "datetime": 1791807288,
                "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More"
              },
              {
                "id": 142819091,
                "url": "https://finnhub.io/api/news?id=471dbe8e44ee052eb30f6c569e370934be3284f5b7ba0d58c5ba598bcbe43d12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- JPMorgan lifted its rating for Biogen to Overweight from Neutral on Monday, pointing to a stronger run of clinical catalysts in 2027 and an improved long-term growth outlook.",
                "category": "company",
                "datetime": 1791805893,
                "headline": "JPMorgan gets bullish on Biogen ahead of 2027 catalysts"
              },
              {
                "id": 142819094,
                "url": "https://finnhub.io/api/news?id=197cda554926ff4bffb812a468f6f11289dc392b1557e6f58842bb3211238b12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.",
                "category": "company",
                "datetime": 1791804818,
                "headline": "BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300"
              },
              {
                "id": 142818618,
                "url": "https://finnhub.io/api/news?id=bf55334356bfe7e1144b5fcce0e6e447dc280a1bcb47e2c450075116711cad84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1791803943,
                "headline": "2 Surging  Stocks for Long-Term Investors and 1 We Brush Off"
              },
              {
                "id": 142821118,
                "url": "https://finnhub.io/api/news?id=9f18d7df53934337e115b97a5d65f47d70dca4bebe046ca327085a633ed5600c",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "JP Morgan  analyst Chris Schott   upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.",
                "category": "company",
                "datetime": 1791792520,
                "headline": "JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300"
              },
              {
                "id": 142822417,
                "url": "https://finnhub.io/api/news?id=a47529ceee0ab307e354aa282be6ff31574e4c12c718fdc96327ce61026e1cee",
                "image": "https://image.cnbcfm.com/api/v1/image/108353411-1787591101647-gettyimages-2271704570-US_STOCKS.jpeg?v=1791803914&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "These are the stocks posting the largest moves in early trading.",
                "category": "company",
                "datetime": 1791790494,
                "headline": "Stocks making the biggest moves premarket: Salesforce, First Solar, Biogen & more"
              },
              {
                "id": 142791726,
                "url": "https://finnhub.io/api/news?id=9b65622705e3e362c7d28e05ef0dad0df47d77c3014d499293dee044acee525e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "UBS  analyst Michael Yee   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $240 to $270.",
                "category": "company",
                "datetime": 1791545871,
                "headline": "UBS Maintains Buy on Biogen, Raises Price Target to $270"
              },
              {
                "id": 142761821,
                "url": "https://finnhub.io/api/news?id=4d18da8f83cbf10d03b8e55007e78b17505bf058240a9eaa589964cca136f7d0",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.",
                "category": "company",
                "datetime": 1791453637,
                "headline": "RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256"
              },
              {
                "id": 142694288,
                "url": "https://finnhub.io/api/news?id=bcf3d87d4790c76efdb9f81b82b264678fd2118cba6bdac7427e6d2884743781",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1687462580/image_1687462580.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Seeking Alpha welcomed 38 new analysts in September 2026. Read more on companies Qualcomm, Teladoc, and NewLake Capital Partners, as well as the TDAQ ETF here.",
                "category": "company",
                "datetime": 1791363600,
                "headline": "Stock Picks From Seeking Alpha's September 2026 New Analysts"
              },
              {
                "id": 142667876,
                "url": "https://finnhub.io/api/news?id=590d600038e76549d58cef880a58e000fde6a8bfa4d2054dc0ba7825564c1b97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development...",
                "category": "company",
                "datetime": 1791306360,
                "headline": "Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says"
              },
              {
                "id": 142667005,
                "url": "https://finnhub.io/api/news?id=48f11ac08d54b3e28cde258398358b2925e7aa8f85da3dab2e94259b8cf24501",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791299406,
                "headline": "Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142662624,
                "url": "https://finnhub.io/api/news?id=dad5fb9983d775cad72c5c2338c949078af0797bb8002c1c8c00ef248e80b39b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791207317,
                "headline": "4 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142623734,
                "url": "https://finnhub.io/api/news?id=5ef42e365d061cd004b39da4a3381f1dc657230a05e8d5dfce4caff85682c00e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2297903713/image_2297903713.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.",
                "category": "company",
                "datetime": 1791108485,
                "headline": "Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027"
              },
              {
                "id": 142591079,
                "url": "https://finnhub.io/api/news?id=3df0e72a2c6efea5ebc369c53b29a52821681a3ceabab71ef718925082530046",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started",
                "category": "company",
                "datetime": 1790954400,
                "headline": "Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus"
              },
              {
                "id": 142590792,
                "url": "https://finnhub.io/api/news?id=510ff0cf1c37661401ef523a1a0e96744fe98ab89cc4cc962cc7fdea3fb87a06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.",
                "category": "company",
                "datetime": 1790946000,
                "headline": "Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?"
              },
              {
                "id": 142614572,
                "url": "https://finnhub.io/api/news?id=c23deb453532ed87d821a806f371c227f93b0b12402bf0229ca8ec0e427ca878",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated",
                "category": "company",
                "datetime": 1790940387,
                "headline": "Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated"
              },
              {
                "id": 142556747,
                "url": "https://finnhub.io/api/news?id=630adcfe3e0f85eada15d3e2b89c416d5339bdaebbf0eeb9bed4bcd20e1ce5ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1790854867,
                "headline": "1 Profitable Stock Worth Investigating and 2 We Ignore"
              },
              {
                "id": 142554444,
                "url": "https://finnhub.io/api/news?id=bece47a1e8fdf58a8f0d6edbe5160ce9e0d5db69bc8bd497806f738745132545",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the \"Board\"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.",
                "category": "company",
                "datetime": 1790852400,
                "headline": "HLS Therapeutics Announces Board of Directors Changes"
              },
              {
                "id": 142476966,
                "url": "https://finnhub.io/api/news?id=e56065f8d8bb86d533d9eb5479d567e55420ae19d538b5fd5211f4c034ab3811",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.",
                "category": "company",
                "datetime": 1790655819,
                "headline": "Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?"
              },
              {
                "id": 142468171,
                "url": "https://finnhub.io/api/news?id=0ffd656afbd32cbc60aff049296e4e6619a3faa131c3e4caa1bbd4259fd96270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.",
                "category": "company",
                "datetime": 1790602860,
                "headline": "Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 82,
            "discarded_article_count": 63
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.2,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日4日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 1269783.3333333333,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1398420,
              "avg_vol_20": 1299750,
              "avg_vol_30": 1269783.3333333333,
              "range_pct_10": 0.10821552827434301,
              "range_pct_20": 0.15849211032380117,
              "range_pct_30": 0.16316328420614684,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1013059970861172,
              "dist_to_20d_high": 0.04072165795369676,
              "down_shrink_days": 2,
              "breakout_level_20d": 254.41,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.663234555499749
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.2639622626843403,
              "turnoverUsdM": 567.346946774148,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 228.1186,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 6.5,
            "take_profit_price": 261.2028,
            "target_multiplier": 1.9,
            "technical_strength": 1.7,
            "take_profit_percent": 7
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.527924525368681,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 7.9657,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.26
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 98.26
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1133
    },
    "kdj": {
      "d": 81.69,
      "j": 62.97,
      "k": 75.45,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 63.32
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 8,
      "trend": "資金入貨",
      "value": 2823684,
      "recentSlope": 127418.4,
      "previousSlope": 127330
    },
    "rsi": 71.37,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 231.1614,
      "position": "SAR喺價下",
      "distancePct": 5.28,
      "previousTrend": "上升"
    },
    "ma50": 225.731,
    "macd": {
      "macd": 7.5691476885090765,
      "trend": "強烈看漲",
      "signal": 6.161825574881254,
      "histogram": 1.4073221136278224
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 235.7299,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 14
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.74,
      "score": 6,
      "avgVolume": 1338321,
      "currentVolume": 2324716
    },
    "derived": {
      "ma20": 234.287,
      "ma50": 225.731,
      "prevClose": 252.73,
      "avgVolume10": 1436182,
      "avgVolume20": 1338321,
      "changePercent": -3.43,
      "avgVolumeForScore": 1338321
    },
    "ma_cross": {
      "ma20": 234.287,
      "ma50": 225.731,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 233.3785,
      "prevMa50": 225.101,
      "spreadPct": 3.79,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 211.2765,
      "upper": 257.2975,
      "position": "上半部"
    },
    "rsi_short": 51.65,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.74
    }
  }
}

Raw metrics JSON

 
{
  "close": 244.05,
  "volume": 2324716,
  "changePercent": -3.43
}

Scores are derived from cached daily market data using the Solorank 110-point standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.